Azitra, Inc. Responds to False Report on Securities Offering
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company, has recently found itself the subject of a misleading report claiming it had launched a $44 million registered direct offering. This report has been unequivocally dismissed as false by the company. Azitra emphasizes that investors and the public should rely solely on official communications from the company.
The company is actively working to trace the origins of this erroneous report to prevent any further misinformation.
Azitra’s Commitment to Transparency
In today’s fast-paced financial landscape, misinformation can quickly spread, causing unnecessary alarm among investors and stakeholders. Azitra understands the importance of clear, honest communication. By urging the public to verify information through its official channels, Azitra is demonstrating its dedication to transparency.
As Azitra continues its journey in precision dermatology, maintaining trust with its community is vital, and the company remains committed to clarity in its dealings.
Innovative Therapies at Azitra
Azitra, Inc. specializes in developing breakthrough therapies for precision dermatology. The company’s flagship program, ATR-12, targets Netherton syndrome, a rare and chronic skin condition that currently lacks approved treatments. This condition can lead to severe complications, particularly in infants. To address this critical need, Azitra is conducting a Phase 1b clinical trial of ATR-12 in adult patients affected by Netherton syndrome.
Additionally, the company’s ATR-04 program aims to provide treatment for rashes associated with EGFR inhibitors, which are commonly prescribed for various cancers. Azitra has received Fast Track designation from the FDA for this program, recognizing the urgent need for effective treatment options for the approximately 150,000 patients affected in the U.S.
The Science Behind Azitra’s Products
Azitra’s innovative approach leverages a proprietary platform that includes engineered proteins and live biotherapeutic products. This platform encompasses a rich microbial library consisting of about 1,500 bacterial strains. In combination with advanced artificial intelligence and machine learning technology, Azitra can analyze and predict outcomes, effectively screening these strains for potential drug-like properties.
The company’s research extends to ATR-01, a preclinical initiative targeting ichthyosis vulgaris, with aspirations for an IND submission in the near future. This breadth of research underscores Azitra’s position at the forefront of dermatological science.
Contact Information
For inquiries, Azitra has made their contact information readily available. Norman Staskey, the Chief Financial Officer, is the primary contact for financial-related queries. Azitra encourages investors and interested parties to reach out for clarity regarding their offerings and commitments.
For investor relations, Tiberend Strategic Advisors, Inc. is available to assist. Jon Nugent can be contacted for additional insights on company activities and ensuring investors receive the most accurate, up-to-date information.
Through effective communication and clear information dissemination, Azitra aims to foster a robust relationship with its stakeholders, built on trust and transparency.
Frequently Asked Questions
What is the false report regarding Azitra, Inc. about?
The false report claimed that Azitra had announced a $44 million registered direct offering, which the company has denied.
How is Azitra ensuring transparency with investors?
Azitra urges investors to rely solely on information released through official company channels and is investigating the source of the misinformation.
What are the main programs Azitra is developing?
Azitra is developing therapies such as ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-associated rash.
What recognition has the ATR-04 program received?
The ATR-04 program has received Fast Track designation from the FDA due to its significant potential to meet an urgent medical need.
How can investors contact Azitra for more information?
Investors can contact Norman Staskey, the CFO, or reach out to Tiberend Strategic Advisors for investor relations inquiries.
